Oncolytics Reports Progression Free Survival Data For Phase 2 Study Of REOLYSIN

(RTTNews) - Oncolytics Biotech Inc. (ONC.TO, ONCY) said that a poster presentation covering progression free survival or PFS and final tumour response data from its U.S. Phase 2 single arm trial in patients with squamous cell carcinoma of the lung or SCCLC using intravenous administration of REOLYSIN combined with carboplatin and paclitaxel, is being made today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

According to the investigators, there were 25 evaluable patients, each of whom had received between two and 12 cycles of therapy. Of the evaluable patients who had more than one cycle of therapy, 23 (92%) exhibited overall tumour shrinkage. When evaluated for best response, which is the best percentage response recorded on study compared to baseline, 10 patients had partial responses, whilst a further 14 exhibited stable disease, and one had progressive disease.

With RECIST criteria's usage to assess best overall response, 10 patients had partial responses, 12 showed stable disease and three had progressive disease.

The conference is being held in Boston, MA from October 19-23.